The Future of Medicine: Helmholtz Munich Opens Innovation Campus
The Helmholtz Pioneer Campus was officially inaugurated today under the slogan "ENGINEERING THE FUTURE OF MEDICINE". Commissioning this new state-of-the-art research facility is a significant milestone for young talents in medical research and…
Targeted Antibody Therapy Against Brain Tumor Glioblastoma
Prof. Reinhard Zeidler about hope in the fight against glioblastoma, the most common and malignant form of brain tumor and how he accelerates the development of antibodies into application.
Helmholtz Munich partners with Medigene to accelerate Tumor Therapy
Helmholtz Munich and Medigene AG expand their partnership in order to further discover and develop T-cell immunotherapies for solid tumors. Medigene acquired from Helmholtz Munich the exclusive, worldwide rights to the CD40L-CD28 Costimulatory Switch…
Targeting Brain Tumors: New Drug Candidate in Clinical Trial
Clinical trials are a milestone in the development of safe and effective drugs and therapies. An antibody developed by Helmholtz Munich is now entering a phase 1 clinical trial. Together with the radiopharmaceutical company ITM Isotope Technologies…
"A startup can be just as big a success as a Leibniz Prize!"
Matthias Tschöp, CEO of Helmholtz Munich, talks about translating scientific discoveries into clinical practice, about ambitious targets, and about ideas he acquired during his time in the USA.
